Russian Heart Failure Journal 2014year Biomarkers of the renin-angiotensin-aldosterone system as predictors of heart failure in obese patients


To access this material please log in or register

Register Authorize
2014/№3

Biomarkers of the renin-angiotensin-aldosterone system as predictors of heart failure in obese patients

Bogdanov A. R., Zaletova T. S., Sentsova T. B., Golubeva A. A., Shcherbakova M. Yu.

Keywords: neurohumoral status, obesity, renin-angiotensin system, heart failure

DOI: 10.18087/rhfj.2014.3.1922

Background. At the present time, obesity is recognized as a major risk factor (RF) of cardiovascular diseases (CVD). Aim. To study pathogenetic mechanisms of neurohumoral activation and their significance for development of HF in obesity. Materials and methods. 78 obese patients were evaluated and divided into two groups, the main group (n=40) consisting of patients with grade 3 obesity (mean BMI, 53.2 kg / m2) and the reference group (n=38) consisting of patients with grade 1 and 2 obesity (mean BMI, 35.9 kg / m2). Clinical and functional manifestations of CHF were studied; plasma levels of N-terminal fragment of brain natriuretic peptide (NT-proBNP), aldosterone, renin and angiotensin II (AII) were measured. These parameters were evaluated at admission and after 14 days of low-calorie, low-sodium diet therapy. Results. 46.2 % of patients with grade 1 and 2 obesity and 85.7 % of patients with grade 3 obesity had increased plasma levels of aldosterone in combination with normal renin and moderately increased AII. Patients with grade 3 obesity had significantly higher plasma levels of aldosterone than patients with grade 1 and 2 obesity (25.9 %, р <0.05). Levels of aldosterone were closely correlated with levels of NT-proBNP (r=0.74, р <0.05) and severity of HF as assessed by the clinical status scale (r=0.54, р <0.05). The low-calorie and low-sodium diet therapy induced a highly significant increase in aldosterone by 23.4 % in patients with grade 1 and 2 obesity (р <0.001) and by 51.2 % (p <0.001) in patients with grade 3 obesity. In addition, patients with grade 3 obesity had two times higher blood level of renin (р=0.01). Conclusion. Progression of obesity is associated with secondary hyperaldosteronism. Plasma levels of aldosterone and renin should be taken into account in selection of treatment tactics for obese patient. If these levels are increased, an appropriate drug therapy should be administered.
  1. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006 Apr 5;295 (13):1549–55.
  2. Nicklas TA, Baranowski T, Cullen KW, Berenson G. Eating patterns, dietary quality and obesity. J Am Coll Nutr. 2001 Dec;20 (6):599–608.
  3. Whitaker RC1, Wright JA, Pepe MS et al. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med. 1997 Sep 25;337 (13):869–73.
  4. Parsons TJ, Power C, Logan S, Summerbell CD. Childhood predictors of adult obesity: a systematic review. Int J Obes Relat Metab Disord. 1999 Nov;23 (Suppl 8):S1–107.
  5. Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension. 2009 Sep;54 (3):462–4.
  6. Whaley-Connell A, Sowers JR. Indices of obesity and cardiometabolic risk. Hypertension. 2011 Dec;58 (6):991–3.
  7. Schenk S1, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008 Sep;118 (9):2992–3002.
  8. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113 (6):898–918.
  9. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347 (5):305–13.
  10. Narkiewicz K, Wolf J, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea and hypertension. Curr Cardiol Rep. 2005 Nov;7 (6):435–40.
  11. Romero-Corral A, Montori VM, Somers VK et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006 Aug 19;368 (9536):666–78.
  12. Юдочкин А. В., Шарафетдинов Х. Х., Плотникова О. А., Стародубова А. В. Современные представления о роли питания и генетических факторов в развитии метаболического синдрома. Вопросы питания. 2011;80 (3):18–24.
  13. Богданов А. Р., Залетова Т. С., Богданов Р. Р. Показатели метаболометрии у больных с заболеваниями сердечно-сосудистой системы и ожирением. Доктор РУ. 2012;10 (78):15–21.
  14. Шамшева Д. С, Голубева А. А. Дыхательные расстройства у пациентов с ожирением. Доктор Ру. 2013;8 (86):57–61.
  15. Sierra-Johnson J, Romero-Corral A, López-Jiménez F. Utility of different lipid measures to predict coronary heart disease. JAMA. 2008 Jan 2;299 (1):35.
  16. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 (7):418–25
  17. Gottdiener JS, Reda DJ, Materson BJ et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol. 1994;24 (6):1492–1498.
  18. Lauer MS, Anderson KM, Kannel WB, Levy D. The impactof obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA. 1991 Jul 10;266 (2):231–6.
  19. Post WS, Levy D. New developments in the epidemiology of left ventricular hypertrophy. Curr Opin Cardiol. 1994 Sep;9 (5):534–41.
  20. Арутюнов Г. П. Терапия ХСН. Всегда ли детерминирован выбор первого препарата? Русский медицинский журнал. 2006;2:137–142.
  21. Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007 Sep;27 (5):529–37.
  22. Ruano M, Silvestre V, Castro R et al. Morbidobesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg. 2005 May;15 (5):670–6.
Bogdanov A.R., Zaletova T.S., Sentsova T.B. et al. Biomarkers of the renin-angiotensin-aldosterone system as predictors of heart failure in obese patients. Russian Heart Failure Journal. 2014;84 (3):160–166

To access this material please log in or register

Register Authorize
Ru En